

Course Syllabus

HECON 530: Global Health Technology Assessment and Market Access

Spring Quarter

Course 3 of 3 in the *Certificate in Health Economics, Health Technology Assessment, and Market Access*

Instructors:

Sean D. Sullivan, BScPharm, PhD, sdsull@uw.edu

Beth Devine, PhD, PharmD, MBA, MSc, bdevine@uw.edu

Course Description

(2025-2026 curriculum; subject to slight changes for 2026-2027)

This course introduces students to the principles, methods, and practices of global HTA and market access. It presents various approaches to organizing and conducting HTA, using examples from around the world. It examines contemporary case studies and presents interviews with global HTA leaders to understand the processes used to evaluate evidence and make resource allocation decisions about health technologies. The course describes and discusses various market access instruments, including price negotiation, innovative access agreements, and international price referencing.

Course Learning Outcomes

By the end of this course, students will be able to:

- Characterize the organization, structure, processes and conduct of the key Health Technology Assessment bodies around the world
- Identify the similarities and differences between key HTA agencies around the world, including the specific processes used to synthesize and appraise evidence to support reimbursement and coverage decisions; and
- Evaluate the role of thresholds, decision rules and innovative financial access agreements by HTA agencies in the current environment.
- Understand and navigate the complexities of international price referencing arrangements
- Describe the emerging price negotiation environment in the U.S.

Course Lessons

- Module 1: Principles of HTA Practice Methods for Developing and Assessing Evidence to Support HTA Practice
 - Lesson 1: History and Core Principles of Health Technology Assessment
 - Lesson 2: Sources and Quality of Evidence for HTA, Parts 1 and 2
 - Lesson 3-1: Evidence Synthesis (Systematic Literature Reviews & Meta-Analysis), Parts 1 & 2
 - Lesson 3-2: Overview of Bayesian Network Meta-Analyses, Parts 1 & 2
 - Lesson 3-3: Bias and Causal Inference, Parts 1 & 2
 - Lesson 4: Transferability of Economic Evidence, Parts 1 and 2
- Module 2: International Practice of HTA
 - Europe
 - Lesson 5: 2025 EU HTA Regulations
 - Interview with Lotte Steuten, PhD
 - Lesson 6: HTA in Germany
 - Interview with Frank-Ulrich Fricke, PhD
 - Lesson 7: HTA in the United Kingdom
 - Interview with Carole Longson, PhD
 - North America
 - Lesson 8: HTA in Canada
 - Interview with Brian O'Rourke, PharmD
 - Lesson 9: HTA in the United States
 - Interview with Daniel Ollendorf, PhD
 - Asia Pacific Region
 - Lesson 10: HTA in Australia
 - Interview with Lili Bulfone, MBA
 - Lesson 11: HTA in Asia Pacific Region
 - Interview with Fei-Yuan Sharon Hsiao, PhD – Taiwan
 - Interview with SeungJin Bae, PhD – South Korea
 - Latin America
 - Lesson 12: HTA in Latin America
 - Interview with Stephen Stefani, MD – Brazil
 - Middle- and Low-Income Countries
 - Lesson 13: HTA in Middle- and Low-Income Countries, Parts 1 and 2
 - Panel Interview on Emerging Markets: Discussion with HTA Experts from the Middle East and North Africa: Mahmoud Diaa, PharmD, Khalil Kadaoui, PhD, and Abdulkadir Keskinaslan, MD, MBA, MPH

- Module 3: Market Access
 - Lesson 14: Vaccines, Medical Devices, and Diagnostics
 - Lesson 15: Decision Rules and Thresholds for Coverage and Reimbursement Decisions
 - Lesson 16: Innovative Market Access Agreements
 - Lesson 17: Medicare Prescription Drug Price Negotiation Program and the Most Favored Nation Drug Pricing Schemes in the US